Evidence map›Paper›PMID 25294900›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014

Team work matters: dual inhibition puts non-hodgkin lymphoma under siege.

Giada Bianchi, Irene M Ghobrial

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Giada BianchiDana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.
Irene M GhobrialDana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts. Irene_Ghobrial@dfci.harvard.edu.
Harvard University · US

Funding

The role of miRNA15a and 16-1 in Multiple MyelomaR01CA154648 · NCI · DANA-FARBER CANCER INST · PI GHOBRIAL, IRENE M. · 2011 to 2015
$1.8M
Stroma-mediated clonal evolution in Multiple MyelomaR01CA181683 · NCI · DANA-FARBER CANCER INST · PI GHOBRIAL, IRENE M. · 2014 to 2018
$1.8M
CXCR4 regulation of tumor progression in Multiple MyelomaR01CA125690 · NCI · DANA-FARBER CANCER INST · PI GHOBRIAL, IRENE M. · 2008 to 2012
$1.6M
NCI NIH HHS R01 CA125690NCI NIH HHS R01CA154648NCI NIH HHS R01CA181683
6 · The paper itself

Abstract

Inhibitors of PI3K/mTOR and histone deacetylases (HDAC) are effective in non-Hodgkin lymphoma (NHL). However, clinical resistance eventually ensues and combinatory therapies are sought to prevent it. Preclinical evaluation of dual PI3K/mTOR and HDAC inhibition is synergistic against NHL, paving the way for bench-to-bedside translation.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansHydroxamic AcidsImidazolesIndolesLymphoma, Large B-Cell, DiffuseQuinolinesSignal TransductionHydroxamic AcidsImidazolesIndolesQuinolines

Identifiers

PMID25294900
PMCPMC4433012
OpenAlexW2166855248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.